Literature DB >> 25919844

The use of psychotropic medication in patients with emotionally unstable personality disorder under the care of UK mental health services.

Carol Paton1, Michael J Crawford, Sumera F Bhatti, Maxine X Patel, Thomas R E Barnes.   

Abstract

BACKGROUND: Guideline recommendations for the pharmacologic treatment of personality disorder lack consensus, particularly for emotionally unstable personality disorder (EUPD), and there is limited information on current prescribing practice in the United Kingdom.
OBJECTIVE: To characterize the nature and quality of current prescribing practice for personality disorder across the United Kingdom, as part of a quality improvement program.
METHOD: A cross-sectional survey of self-selected psychiatric services providing care for adults with personality disorder (ICD-10 criteria) was conducted. Data were collected during May 2012.
RESULTS: Of 2,600 patients with a diagnosis of personality disorder, more than two-thirds (68%) had a diagnosis of EUPD. Almost all (92%) patients in the EUPD subgroup were prescribed psychotropic medication, most commonly an antidepressant or antipsychotic, principally for symptoms and behaviors that characterize EUPD, particularly affective dysregulation. Prescribing patterns were similar between those who had a diagnosed comorbid mental illness and those who had EUPD alone, but the latter group was less likely to have had their medication reviewed over the previous year, particularly with respect to tolerability (53% vs 43%).
CONCLUSIONS: The use of psychotropic medication in EUPD in the United Kingdom is largely outside the licensed indications. Whether the treatment target is identified as intrinsic symptoms of EUPD or comorbid mental illness may depend on the diagnostic threshold of individual clinicians. Compared with prescribing for EUPD where there is judged to be a comorbid mental illness, the use of off-label medication for EUPD alone is less systematically reviewed and monitored, so opportunities for learning may be lost. Treatment may be continued long term by default. © Copyright 2015 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25919844     DOI: 10.4088/JCP.14m09228

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  16 in total

Review 1.  A Focused Systematic Review of Pharmacological Treatment for Borderline Personality Disorder.

Authors:  Ella Hancock-Johnson; Chris Griffiths; Marco Picchioni
Journal:  CNS Drugs       Date:  2017-05       Impact factor: 5.749

2.  The State of Overmedication in Borderline Personality Disorder: Interpersonal and Structural Factors.

Authors:  Rosa Shapiro-Thompson; Sarah K Fineberg
Journal:  Curr Treat Options Psychiatry       Date:  2022-03-04

3.  The clinical effectiveness and cost effectiveness of clozapine for inpatients with severe borderline personality disorder (CALMED study): a randomised placebo-controlled trial.

Authors:  Mike J Crawford; Verity C Leeson; Rachel Evans; Barbara Barrett; Aisling McQuaid; Jack Cheshire; Rahil Sanatinia; Gary Lamph; Piyal Sen; Katina Anagnostakis; Louise Millard; Inti Qurashi; Fintan Larkin; Nusrat Husain; Paul Moran; Thomas R E Barnes; Carol Paton; Zoe Hoare; Marco Picchioni; Simon Gibbon
Journal:  Ther Adv Psychopharmacol       Date:  2022-04-29

4.  What are the barriers to, and enablers of, working with people with lived experience of mental illness amongst community and voluntary sector organisations? A qualitative study.

Authors:  Louise Baxter; Daisy Fancourt
Journal:  PLoS One       Date:  2020-07-02       Impact factor: 3.240

5.  Dissociative states in borderline personality disorder and their relationships to psychotropic medication.

Authors:  Ondrej Pec; Petr Bob; Jakub Simek; Jiri Raboch
Journal:  Neuropsychiatr Dis Treat       Date:  2018-11-23       Impact factor: 2.570

Review 6.  A Life Span Perspective on Borderline Personality Disorder.

Authors:  Arjan C Videler; Joost Hutsebaut; Julie E M Schulkens; Sjacko Sobczak; Sebastiaan P J van Alphen
Journal:  Curr Psychiatry Rep       Date:  2019-06-04       Impact factor: 5.285

Review 7.  Pharmacotherapy for Borderline Personality Disorder: an Update of Published, Unpublished and Ongoing Studies.

Authors:  Jutta Stoffers-Winterling; Ole Jakob Storebø; Klaus Lieb
Journal:  Curr Psychiatry Rep       Date:  2020-06-05       Impact factor: 5.285

8.  Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology.

Authors:  G M Goodwin; P M Haddad; I N Ferrier; J K Aronson; Trh Barnes; A Cipriani; D R Coghill; S Fazel; J R Geddes; H Grunze; E A Holmes; O Howes; S Hudson; N Hunt; I Jones; I C Macmillan; H McAllister-Williams; D R Miklowitz; R Morriss; M Munafò; C Paton; B J Saharkian; Kea Saunders; Jma Sinclair; D Taylor; E Vieta; A H Young
Journal:  J Psychopharmacol       Date:  2016-03-15       Impact factor: 4.153

9.  Twenty-Year Trends in the Psychopharmacological Treatment of Outpatients with Borderline Personality Disorder: A Cross-Sectional Naturalistic Study in Spain.

Authors:  Juan C Pascual; Ana Martín-Blanco; Joaquim Soler
Journal:  CNS Drugs       Date:  2021-08-09       Impact factor: 5.749

10.  Second-generation antipsychotic use in borderline personality disorder: What are we targeting?

Authors:  Adrian Wasylyshen; Andrew M Williams
Journal:  Ment Health Clin       Date:  2016-03-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.